Differential antiangiogenic and anticancer activities of the active metabolites of ginsenoside Rg3

[1]  T. Price,et al.  Anti-Angiogenic Properties of Ginsenoside Rg3 Epimers: In Vitro Assessment of Single and Combination Treatments , 2021, Cancers.

[2]  Sirui Zhu,et al.  20(S)-ginsenoside Rh2 induces caspase-dependent promyelocytic leukemia-retinoic acid receptor A degradation in NB4 cells via Akt/Bax/caspase9 and TNF-α/caspase8 signaling cascades , 2020, Journal of ginseng research.

[3]  T. Price,et al.  Anti-Angiogenic Properties of Ginsenoside Rg3 , 2020, Molecules.

[4]  Min Wang,et al.  20(S)-Ginsenoside Rh2 displays efficacy against T-cell acute lymphoblastic leukemia through the PI3K/Akt/mTOR signal pathway , 2019, Journal of ginseng research.

[5]  Linlin Pan,et al.  Ginsenoside Rg3 (Shenyi Capsule) Combined with Chemotherapy for Digestive System Cancer in China: A Meta-Analysis and Systematic Review , 2019, Evidence-based complementary and alternative medicine : eCAM.

[6]  M. Speir,et al.  Flipping the dogma – phosphatidylserine in non-apoptotic cell death , 2019, Cell Communication and Signaling.

[7]  M. Okada,et al.  Targeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma , 2019, Cell Communication and Signaling.

[8]  Joanne P Young,et al.  Bacopasides I and II Act in Synergy to Inhibit the Growth, Migration and Invasion of Breast Cancer Cell Lines , 2019, Molecules.

[9]  T. Price,et al.  Stereoselective Anti-Cancer Activities of Ginsenoside Rg3 on Triple Negative Breast Cancer Cell Models , 2019, Pharmaceuticals.

[10]  D. Baker,et al.  Intratumoral activation of the necroptotic pathway components RIPK1 and RIPK3 potentiates antitumor immunity , 2019, Science Immunology.

[11]  Chao Yang,et al.  The role of necroptosis in cancer biology and therapy , 2019, Molecular Cancer.

[12]  Wenchen Pu,et al.  Circular RNA F-circSR derived from SLC34A2-ROS1 fusion gene promotes cell migration in non-small cell lung cancer , 2019, Molecular Cancer.

[13]  T. Price,et al.  Bumetanide-Derived Aquaporin 1 Inhibitors, AqB013 and AqB050 Inhibit Tube Formation of Endothelial Cells through Induction of Apoptosis and Impaired Migration In Vitro , 2019, International journal of molecular sciences.

[14]  T. Price,et al.  Ginsenoside Rg3: Potential Molecular Targets and Therapeutic Indication in Metastatic Breast Cancer , 2019, Medicines.

[15]  Tong Zhang,et al.  20(S)‐protopanaxadiol induces apoptosis in human umbilical vein endothelial cells by activating the PERK‐eIF2alpha‐ATF4 signaling pathway , 2018, Journal of cellular biochemistry.

[16]  Joanne P Young,et al.  The Purified Extract from the Medicinal Plant Bacopa monnieri, Bacopaside II, Inhibits Growth of Colon Cancer Cells In Vitro by Inducing Cell Cycle Arrest and Apoptosis , 2018, Cells.

[17]  Michael L. De Ieso,et al.  Mechanisms of Aquaporin-Facilitated Cancer Invasion and Metastasis , 2018, Front. Chem..

[18]  Jin Yao,et al.  Ginsenoside Rh2 inhibits vascular endothelial growth factor‐induced corneal neovascularization , 2018, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[19]  J. Carroll,et al.  Novel Androgen Receptor Coregulator GRHL2 Exerts Both Oncogenic and Antimetastatic Functions in Prostate Cancer. , 2017, Cancer research.

[20]  T. Price,et al.  Role of Aquaporin 1 Signalling in Cancer Development and Progression , 2017, International journal of molecular sciences.

[21]  Michael L. De Ieso,et al.  Differential Inhibition of Water and Ion Channel Activities of Mammalian Aquaporin-1 by Two Structurally Related Bacopaside Compounds Derived from the Medicinal Plant Bacopa monnieri , 2016, Molecular Pharmacology.

[22]  R. Kong,et al.  Clinical benefit from EGFR-TKI plus ginsenoside Rg3 in patients with advanced non-small cell lung cancer harboring EGFR active mutation , 2016, Oncotarget.

[23]  J. Wen,et al.  Ginsenoside Rh2 inhibiting HCT116 colon cancer cell proliferation through blocking PDZ-binding kinase/T-LAK cell-originated protein kinase , 2016, Journal of ginseng research.

[24]  M. Peng,et al.  Stereoselective pharmacokinetic and metabolism studies of 20(S)- and 20(R)-ginsenoside Rg₃ epimers in rat plasma by liquid chromatography-electrospray ionization mass spectrometry. , 2016, Journal of pharmaceutical and biomedical analysis.

[25]  Wei Zhang,et al.  Prospective Study of Transcatheter Arterial Chemoembolization (TACE) with Ginsenoside Rg3 versus TACE Alone for the Treatment of Patients with Advanced Hepatocellular Carcinoma. , 2016, Radiology.

[26]  I. Lavrik,et al.  Quantification of apoptosis and necroptosis at the single cell level by a combination of Imaging Flow Cytometry with classical Annexin V/propidium iodide staining. , 2015, Journal of immunological methods.

[27]  Qiang Z Yu,et al.  Apoptosis, autophagy, necroptosis, and cancer metastasis , 2015, Molecular Cancer.

[28]  V. Ponomarev,et al.  Doxorubicin overcomes resistance to drozitumab by antagonizing Inhibitor of Apoptosis Proteins (IAPs). , 2014, Anticancer research.

[29]  Arthur Christopoulos,et al.  Allosteric targeting of receptor tyrosine kinases , 2014, Nature Biotechnology.

[30]  Yingqi Hua,et al.  The anti-tumor effect of shikonin on osteosarcoma by inducing RIP1 and RIP3 dependent necroptosis , 2013, BMC Cancer.

[31]  Per Karlsson,et al.  Elevated cyclin B2 expression in invasive breast carcinoma is associated with unfavorable clinical outcome , 2013, BMC Cancer.

[32]  F. Winkler,et al.  Thermodynamic and structural description of allosterically regulated VEGFR-2 dimerization. , 2012, Blood.

[33]  R. Kondo,et al.  Stereospecificity of hydroxyl group at C-20 in antiproliferative action of ginsenoside Rh2 on prostate cancer cells. , 2010, Fitoterapia.

[34]  A. Yool,et al.  Roles for novel pharmacological blockers of aquaporins in the treatment of brain oedema and cancer , 2010, Clinical and experimental pharmacology & physiology.

[35]  Shivendra V. Singh,et al.  Ginsenoside Rh2-mediated G1 Phase Cell Cycle Arrest in Human Breast Cancer Cells Is Caused by p15Ink4B and p27Kip1-dependent Inhibition of Cyclin-dependent Kinases , 2009, Pharmaceutical Research.

[36]  Xun Hu,et al.  Naturally-occurring shikonin analogues--a class of necroptotic inducers that circumvent cancer drug resistance. , 2009, Cancer letters.

[37]  P. Lu,et al.  Effect and mechanism of ginsenoside Rg3 on postoperative life span of patients with non-small cell lung cancer , 2008 .

[38]  R. Kasai,et al.  Antitumor agents. 261. 20(S)-protopanaxadiol and 20(s)-protopanaxatriol as antiangiogenic agents and total assignment of (1)H NMR spectra. , 2008, Journal of natural products.

[39]  J. Christensen,et al.  A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[40]  Jianhong Luo,et al.  Shikonin circumvents cancer drug resistance by induction of a necroptotic death , 2007, Molecular Cancer Therapeutics.

[41]  I. Tucker,et al.  High performance liquid chromatographic-mass spectrometric determination of ginsenoside Rg3 and its metabolites in rat plasma using solid-phase extraction for pharmacokinetic studies. , 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[42]  J. Griffin,et al.  Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease-activated receptor-1 and endothelial cell protein C receptor. , 2003, The Biochemical journal.